Sec. 789. Increased collaboration with NIH to combat triple negative breast cancer
166 words·~1 min read·
/bill/117/hr/7900/eh/section-789·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Office of Health of the Department of Defense shall work in collaboration with the National Institutes of Health to— identify specific genetic and molecular targets and biomarkers for triple negative breast cancer; and provide information useful in biomarker selection, drug discovery, and clinical trials design that will enable both— triple negative breast cancer patients to be identified earlier in the progression of their disease; and the development of multiple targeted therapies for the disease.
Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated by section 1405 for the Defense Health Program, as specified in the corresponding funding tables in division D, is hereby increased by $10,000,000 to carry out subsection (a). Notwithstanding the amounts set forth in the funding tables in division D, the amount authorized to be appropriated by section 1405 for the Defense Health Program, as specified in the corresponding funding tables in division D, for Private Sector Care is hereby reduced by $10,000,000.